New Product Launch: Nuwellis, Inc. plans to introduce a new 24-hour circuit for Aquadex therapy in the U.S. this fall, designed for single-day outpatient sessions, complementing the existing 72-hour option for multi-day therapy.
Outpatient Care Expansion: The new circuit aims to support hospitals in building outpatient Aquadex programs, providing a reliable and efficient pathway for fluid removal without hospital admission, enhancing patient care and clinic operations.
NUWE
$2.21+Infinity%1D
Analyst Views on NUWE
Wall Street analysts forecast NUWE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUWE is 3.90 USD with a low forecast of 3.90 USD and a high forecast of 3.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast NUWE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUWE is 3.90 USD with a low forecast of 3.90 USD and a high forecast of 3.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 2.160
Low
3.90
Averages
3.90
High
3.90
Current: 2.160
Low
3.90
Averages
3.90
High
3.90
Roth Capital
Jonathan Aschoff
Buy
downgrade
$13 -> $11
2025-05-13
Reason
Roth Capital
Jonathan Aschoff
Price Target
$13 -> $11
2025-05-13
downgrade
Buy
Reason
Roth Capital analyst Jonathan Aschoff lowered the firm's price target on Nuwellis to $11 from $13 and keeps a Buy rating on the shares. While the company's Q1 revenue was down 18% quarter over quarter, pediatric utilization grew 38% year over year, the analyst tells investors in a research note. The firm believes that the four-fold increase in Aquadex Centers for Medicare & Medicaid Services reimbursement should support future revenue growth.
About NUWE
Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
